Search

Your search keyword '"Nakamura, Ryotaro"' showing total 115 results

Search Constraints

Start Over You searched for: Author "Nakamura, Ryotaro" Remove constraint Author: "Nakamura, Ryotaro" Journal biology of blood and marrow transplantation Remove constraint Journal: biology of blood and marrow transplantation
115 results on '"Nakamura, Ryotaro"'

Search Results

1. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes

3. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia

4. Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

5. Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center

7. Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

8. Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia

10. Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 Study Rationale, Design, and Methods

16. Impact of Graft Cell Dose on Transplant Outcomes following Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation: Higher CD34 + Cell Doses Are Associated with Decreased Relapse Rates

20. Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network

22. A Phase II Trial of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation

23. Assessment of Anti-Oxidant Markers of Inflammation in Patients with Chronic Graft-Versus-Host Disease

25. Comparison of Transplant Outcomes in Patients with Acute Lymphoblastic Leukemia after Haploidentical Transplant with Post-Transplant Cyclophosphamide or Matched Unrelated Donor Transplant

26. A Phase 2 Study of F-652, a Novel Tissue-Targeted Recombinant Human Interleukin-22 (IL-22) Dimer, for Treatment of Newly Diagnosed Acute Gvhd of the Lower GI Tract

27. Impact of Genetic Mutations on the Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia with Antecedent Myeloproliferative Neoplasm

28. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease

30. The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future

33. A Pilot Phase II Trial of Combining Extracorporeal Photopheresis (ECP) and Low Dose IL-2 for Treatment of Sclerodermatous Steroid Refractory Chronic Graft-Versus-Host Disease (cGvHD)

34. Pulmonary Arterial Hypertension (PAH) Is Associated with Increased Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation (allo HCT) for Myelofibrosis

36. HLA-Matched Sibling Versus Haploidentical Hematopoietic Cell Transplantation (HCT) in Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)

37. Real World Experience of Letermovir (LTV) Prophylaxis (Px) for the Prevention of Cytomegalovirus Infection (CMVi) in the Adult CMV Seropositive Recipients (R+) of Allogeneic Hematopoietic Cell Transplantation (HCT) Patients (pts).

38. A Retrospective Study of Venetoclax-Based Salvage Regimen As a Bridge to Allogeneic Hematopoietic Cell Transplantation (HCT) in High-Risk Acute Myeloid Leukemia (AML) Patients

39. A Retrospective Study of Blinatumomab Based Salvage Regimen As a Bridge to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed and Refractory ALL

41. Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis

42. Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease

43. 95 - Biomarkers Predict Graft-Vs-Host Disease Outcomes Better Than Clinical Response after One Week of Treatment

44. 440 - An Early Biomarker Algorithm Predicts Lethal Graft-Vs-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation

46. Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis

47. Transplant Outcomes in Patients with AML Carrying IDH 1 and 2 Mutations: Retrospective Study From a Single Center Experience

49. Ibrutinib for Chronic Graft-Versus-Host Disease: A Safety and Pharmacokinetic Analysis in Patients Treated with Concomitant Antifungal CYP3A Inhibitors or Immunosuppressants

Catalog

Books, media, physical & digital resources